1351635-67-0 Usage
Description
ONO-4059 is a potent and selective inhibitor of Bruton's tyrosine kinase (BTK), a non-receptor tyrosine kinase that plays a crucial role in the activation and survival of B cells. It is a small molecule analog that has been developed to target BTK with high specificity, making it a promising pharmaceutical candidate for various applications.
Uses
Used in Pharmaceutical Industry:
ONO-4059 is used as a therapeutic agent for the treatment of B cell-mediated diseases, such as autoimmune disorders and B cell malignancies. By inhibiting BTK, it can modulate the activation and survival of B cells, leading to the suppression of disease progression and improvement of patient outcomes.
Used in Oncology:
ONO-4059 is used as an anticancer agent, particularly for the treatment of B cell malignancies such as chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL), and acute lymphoblastic leukemia (ALL). It targets the BTK pathway, which is essential for the growth and survival of malignant B cells, leading to the inhibition of tumor growth and improved treatment outcomes.
Used in Drug Delivery Systems:
To enhance the efficacy and bioavailability of ONO-4059, various drug delivery systems have been developed. These systems aim to improve the solubility, stability, and targeted delivery of the compound, resulting in enhanced therapeutic effects and reduced side effects.
in vitro
ono-4059 inhibited the tmd-8 cell growth and btk phosphorylation in a concentration-dependent manner. furthermore, the decrease in btk phosphorylation subsequently down-regulated erk phosphorylation. after the combination of ono-4059 with doxorubicin, etoposide, vincristine and dexamethasone, increased apoptosis ratio was observed, 25, 20, 17 and 29%, respectively [1].
in vivo
for the 100-200 mm3 tumour groups, tumour growth inhibition at the final treatment day was 23% in qd, 72.9% in bd and 100% in dose mixed in food, groups respectively. for the 400-450 mm3 tumour groups, no growth inhibition was observed in the qd group and, growth inhibitions of 27.5% in bd and 100% in dose mixed in food were observed. the pk concentration and phosphorylated btk inhibition levels of those animals whose dose was mixed in with food were higher than that of other treatment groups [2].
IC 50
2.2 nm for btk kinase activity
references
[1] tomoko yasuhiro, toshio yoshizawa, joseph tp birkett, and kazuhito kawabata. ono-4059, a novel bruton’s tyrosine kinase (btk) inhibitor: synergistic activity in combination with chemotherapy in a abc-dlbcl cell line. 2013; blood: 122 (21): 5151 - 5151[2] toshio yoshizawa, tomoko yasuhiro, hideyuki honda, and kazuhito kawabata. ono-4059—a potent and selective reversible bruton’s tyrosine kinase (btk) inhibitor: single agent, twice daily (bd) dosing and dosing with food results in sustained, high trough levels of ono-4059, translating into 100% tumour remission in a tmd-8 xenograft model. 2014; blood: 124 (21) 4502 - 4502[3] simon rule, nimish shah, gilles andre salles et al. a phase i study of the oral btk inhibitor ono-4059 in patients with relapsed/refractory b-cell lymphoma. blood. 2013 122 (21): 4397 – 4397.
Check Digit Verification of cas no
The CAS Registry Mumber 1351635-67-0 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,5,1,6,3 and 5 respectively; the second part has 2 digits, 6 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 1351635-67:
(9*1)+(8*3)+(7*5)+(6*1)+(5*6)+(4*3)+(3*5)+(2*6)+(1*7)=150
150 % 10 = 0
So 1351635-67-0 is a valid CAS Registry Number.
1351635-67-0Relevant articles and documents
PURINONE DERIVATIVE
-
Paragraph 0188; 0189; 0192; 0201; 0202, (2013/04/10)
Compounds represented by general formula (I) (all of the symbols in the formula conform to the definitions in the Description) are compounds that, in addition to having a Btk-selective inhibitory activity, exhibit an excellent metabolic stability and can avoid hepatotoxicity or the like, and as a consequence can provide safe therapeutic agents for diseases in which B cells or mast cells participate.
